Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
The ESC HF III Registry found substantial mortality and rehospitalization across heart failure phenotypes. Risk was highest after acute hospitalization and generally worse with reduced ejection fraction, but HFmrEF and HFpEF also carried si
In a large Medicare study, multiarterial grafting after CABG looked beneficial in standard analysis, but the advantage disappeared with instrumental variable adjustment, suggesting earlier observational studies may have overestimated surviv
In patients with prior PCI but no prior MI, evolocumab significantly lowered LDL-C and reduced major cardiovascular events, including myocardial infarction and urgent revascularization, supporting intensive lipid lowering after coronary int
A multicenter emergency department study found that CPES performed similarly to sPESI and ESC for short-term PE outcomes, but it better predicted the need for advanced intervention.
In CTEPH patients undergoing balloon pulmonary angioplasty, dual pulmonary hypertension-targeted pretreatment was linked to fewer thoracic complications and better 6-month clinical improvement than monotherapy.
In the REGARDS cohort, prior myocardial infarction, including silent MI, was linked to faster long-term cognitive decline, suggesting heart attack history may help identify people at risk for future cognitive impairment.
A 24-month randomized trial found that exercise, intensive blood pressure and cholesterol control, or both together did not significantly improve cognitive function in older adults at increased risk for dementia.
Post-hoc metabolomic and lipidomic analyses from two phase 2 trials suggest retatrutide favorably remodels metabolic pathways linked to fatty acid oxidation, insulin resistance, and triglyceride composition in obesity, with and without type
A qualitative study in heart failure shows that medication adherence is shaped by regimen complexity, diuretic burden, psychosocial stressors, cost, and care coordination rather than motivation alone.
This review analyzes the landmark SWISS-AF study, demonstrating that serum neurofilament light chain (sNfL), traditionally a marker of neuronal damage, is a potent independent predictor of major vascular events, heart failure, and mortality
This pooled analysis found that CPAP may lower cardiovascular event risk mainly in patients with high-risk obstructive sleep apnoea, especially those with stronger heart-rate surges or greater oxygen deprivation during sleep.
Three-year LIFE-BTK data show sustained patency and reintervention benefits with a drug-eluting resorbable scaffold versus angioplasty in selected patients with infrapopliteal CLTI, with comparable limb salvage and safety.
Laroprovstat, an investigational oral PCSK9 inhibitor, was well tolerated and produced substantial LDL cholesterol reductions, especially when combined with rosuvastatin, supporting further development for hypercholesterolemia.
Gene therapy for cardiomyopathy is moving from concept to clinic, but durable benefit will depend on solving delivery, immunogenicity, cargo, and safety barriers in the failing human heart.
TRISCEND II showed that transcatheter tricuspid valve replacement with EVOQUE markedly reduced tricuspid regurgitation and improved clinical outcomes across baseline severity levels, with a stronger signal for benefit in massive or torrenti
A large multicohort and experimental study suggests the cTnI/cTnT ratio is biologically informative, separates acute from chronic myocardial injury, and modestly improves type 1 versus type 2 MI discrimination.
In symptomatic HFpEF with atrial functional mitral regurgitation, sacubitril/valsartan improved exercise hemodynamics, peak VO2, symptoms, biomarkers, and stress-induced MR burden over 6 months versus standard care.
COPD exacerbations significantly increase cardiovascular risk for months. This article examines the link between COPD and heart disease, emphasizing proactive screening during flare-ups and evidence-based prevention strategies to improve su
A large Dutch primary care cohort links subclinical hyperthyroidism to higher risks of atrial fibrillation, heart failure, and all-cause mortality, with particularly notable relative risks in younger adults and in patients with more strongl
CARDIO-TTRansform is a global Phase 3 trial evaluating eplontersen’s efficacy and safety in reducing cardiovascular events in transthyretin amyloid cardiomyopathy patients receiving standard care, including TTR stabilizers. With 1,432
Open language-specific specialty feeds and department pages.